Data from the Columbia University Department of Urology demonstrates that Zyflamend, a unique patented herbal extract formulation from New Chapter, has the ability, in vitro, to suppress the growth of prostate cancer cells by as much as 78% and induce prostate cancer cells to self-destruct via a process called “apoptosis.”
The research, published in the October edition of Nutrition and Cancer, also confirms Zyflamend has COX-1 and COX-2 anti-inflammatory effects, although its anticancer affects against prostate cancer were independent of COX-2 inhibition, supporting the postulation that some prostate cancer cells are not affected by COX-2 inflammation.
Based on this research, Zyflamend shows value in early therapy for prostate cancer patients. COX inhibitors have also shown value for prostate cancer patients, but data from recent trials of selective COX-2 inhibitors, such as celecoxib (Celebrex®), suggest that use of these drugs might have adverse cardiovascular effects.
On the strength of this laboratory research, Columbia University’s Department of Urology has commenced a Phase 1 human clinical trial testing Zyflamend’s ability to prevent prostate cancer in patients with prostatic intraepithelial neoplasia (PIN). PIN is a clinical precursor for prostate cancer. Without intervention, men diagnosed with PIN have a 50 to 70% likelihood of developing prostate cancer.
“We are encouraged that this study provides additional scientific evidence that specific herbal preparations can produce a positive impact on prostate health,” said Mark Blumenthal, founder and executive director of the non-profit American Botanical Council.
Adapted from a news release issued by Columbia University Medical Center.